Company: CERO
Filing Date: 2025-11-17
Form Type: PRE 14A
Source: 0001213900-25-111175
Chunk: 18

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-17
Form: PRE 14A
Chunk 18
---
 of our Common Stock as a viable investment security. Lower -pricedstocks have a perception in the investment community as being risky and speculative, which may negatively impact not only the price of our Common Stock, but also our market liquidity. Risks Associated with the Reverse Stock Split There are risks associated with the Reverse Stock Split, including that the Reverse Stock Split may not result in an increase in the per share price of our Common Stock. The Company cannot predict whether the Reverse Stock Split will increase the market price for our Common Stock. The history of similar stock split combinations for companies in like circumstances is varied. There is no assurance that: •the market price per share will maintain the $1.00 minimum bid price requirement for listing by Nasdaq; •the market price per share of our Common Stock after the Reverse Stock Split will rise in proportion to the reduction in the number of shares of our Common Stock outstanding before the effective time of the Reverse Stock Split (the “Effective Time”); 8 •the Reverse Stock Split will result in a per share price that will attract brokers and investors who do not trade in lower -pricedstocks; •the Reverse Stock Split will result in a per share price that will increase the ability of the Company to attract and retain employees; and •the Reverse Stock Split would promote greater liquidity for our shareholders with respect to their shares. We are also currently not in compliance with the minimum stockholders’ equity requirement for continued listing of our Common Stock on Nasdaq and the Reverse Stock Split will not affect our ability to regain compliance with such requirement. In addition, the Reverse Stock Split would reduce the number of outstanding shares of our Common Stock without reducing the number of shares of available but unissued Common Stock, increasing the number of authorized but unissued shares of Common Stock. Therefore, the number of shares of our Common Stock that are authorized and unissued will increase relative to the number of issued and outstanding shares of our Common Stock following the Reverse Stock Split. The Board may authorize the issuance of the remaining authorized and unissued shares without further stockholder action for a variety of purposes, except as such shareholder approval may be required in particular cases by our Certificate of Incorporation, applicable law, or the rules of any stock exchange on which our securities may then be listed. The issuance of additional shares would be dilutive to our existing shareholders and may cause a decline in the trading price of our Common Stock. The market price of our Common Stock will also be based on the performance of the Company and other factors, some of which are